Kymera Therapeutics Presents New Preclinical Data For KT-579, Selective, Oral IRF5 Degrader, Demonstrating Disease-Modifying Activity In Lupus Models, At EULAR And FOCIS Congresses

뉴스 본문을 불러오고 있어요.

Kymera Therapeutics Presents New Preclinical Data For KT-579, Selective, Oral IRF5 Degrader, Demonstrating Disease-Modifying Activity In Lupus Models, At EULAR And FOCIS Congresses | 웨이프 WAPE

Kymera Therapeutics Presents New Preclinical Data For KT-579, Selective, Oral IRF5 Degrader, Demonstrating Disease-Modifying Activity In Lupus Models, At EULAR And FOCIS Congresses

기사 요약

관련 종목

댓글 —